Download PDF
Semin intervent Radiol 2006; 23(1): 021-032
DOI: 10.1055/s-2006-939838
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Positron Emission Tomography for Staging and Assessment of Tumor Response of Hepatic Malignancies

Robert S. Hellman1 , Arthur Z. Krasnow1 , Gary S. Sudakoff1
  • 1Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
Further Information

Publication History

Publication Date:
04 April 2006 (online)

Also available at
    Permissions and Reprints

ABSTRACT

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a useful functional imaging method that complements conventional anatomic imaging modalities for screening patients with colorectal hepatic metastases and hepatocellular cancer to determine their suitability for interventional procedures. FDG PET is more sensitive in detecting colorectal cancer than hepatocellular cancer (~90% versus ~50%). The likelihood of detecting hepatic malignancy with FDG PET rapidly diminishes for lesions smaller than 1 cm. The greatest value of FDG PET in these patients is in excluding extrahepatic disease that might lead to early recurrence after interventional therapy. Promising results have been reported with FDG PET that may show residual (local) or recurrent disease before conventional imaging methods in patients receiving interventional therapy. For patients with colorectal hepatic metastases, many investigators believe that patients with PET evidence of recurrent hepatic disease should receive additional treatment even when there is no confirmatory evidence present on other methodologies. For patients with hepatocellular cancer no conclusions regarding the value of FDG PET for assessment of response to interventional therapy can be reached as there is almost no published data.

KEYWORDS

PET - FDG - colorectal cancer - hepatocellular cancer

REFERENCES

  • 1 Bos R, van der Hoeven J, van der Wall E et al.. Biologic correlates of 18-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.  J Clin Oncol. 2002;  20 379-387
    CrossrefPubMedGoogle Scholar
  • 2 Antoch G, Fruedenberg L S, Beyer T et al.. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.  J Nucl Med. 2004;  45 56S-65S
    PubMedGoogle Scholar
  • 3 Wahl R. Principles of cancer imaging with fluorodeoxy glucose. In: Wahl R, Buchanan J Principles and Practice of Positron Emission Tomography. Philadelphia; Lippincott Williams and Wilkins 2002: 100-110
    Google Scholar
  • 4 Dimitrakopoulou-Strauss A, Strauss L G, Burger C et al.. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.  J Nucl Med. 2004;  45 1480-1487
    PubMedGoogle Scholar
  • 5 Truant S, Huglo D, Hebbar M et al.. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of respectable colorectal liver metastases.  Br J Surg. 2005;  92 362-369
    CrossrefPubMedGoogle Scholar
  • 6 Strasberg S M, Dehdashti F, Siegel B A, Drebin J A, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.  Ann Surg. 2001;  233 293-299
    PubMedGoogle Scholar
  • 7 Fernandez F G, Drebin J A, Linehan D C et al.. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).  Ann Surg. 2004;  240 438-450
    CrossrefPubMedGoogle Scholar
  • 8 Kinkel K, Lu Y, Both M et al.. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.  Radiology. 2002;  224 748-756
    CrossrefPubMedGoogle Scholar
  • 9 Huebner R H, Park K C, Shepherd J E et al.. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.  J Nucl Med. 2000;  41 1177-1189
    PubMedGoogle Scholar
  • 10 Lonneux M, Reffad A M, Detry R, Kartheuser A, Gigot J F, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.  Eur J Nucl Med Mol Imaging. 2002;  29 915-921
    CrossrefPubMedGoogle Scholar
  • 11 Kalff V, Hicks R J, Ware R E et al.. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study.  J Nucl Med. 2002;  43 492-499
    PubMedGoogle Scholar
  • 12 Whiteford M H, Whiteford H M, Yee L F et al.. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.  Dis Colon Rectum. 2000;  43 759-767
    CrossrefPubMedGoogle Scholar
  • 13 Rohren E M, Paulson E K, Hagge R et al.. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer.  Clin Nucl Med. 2002;  27 550-555
    CrossrefPubMedGoogle Scholar
  • 14 Rydzewski B, Dehdashti F, Gordon B A, Teefey S A, Strasberg S M, Siegel B A. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET.  AJR Am J Roentgenol. 2002;  178 353-358
    PubMedGoogle Scholar
  • 15 Numminen K, Isoniemi H, Halavaara J et al.. Preoperative assessment of focal liver lesions: multidetector computed tomography challenges magnetic resonance imaging.  Acta Radiol. 2005;  46 9-15
    CrossrefPubMedGoogle Scholar
  • 16 Selzner M, Hany T F, Wildbrett P et al.. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?.  Ann Surg. 2004;  240 1027-1036
    CrossrefPubMedGoogle Scholar
  • 17 Hussain S M, Zondervan P E, Ijzermans J NM et al.. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation.  Radiographics. 2002;  22 1023-1039
    PubMedGoogle Scholar
  • 18 Okazumi S, Isono K, Enomoto K et al.. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.  J Nucl Med. 1992;  33 333-339
    PubMedGoogle Scholar
  • 19 Ho C, Yu S CH, Yeung D WC. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.  J Nucl Med. 2003;  44 213-221
    PubMedGoogle Scholar
  • 20 Khan M A, Combs C S, Brunt E M et al.. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.  J Hepatol. 2000;  32 792-797
    CrossrefPubMedGoogle Scholar
  • 21 Wudel L J, Delbeke D, Morris D et al.. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.  Am Surg. 2003;  69 117-126
    PubMedGoogle Scholar
  • 22 Shiomi S, Hishiguchi S, Ishizu H et al.. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.  Am J Gastroenterol. 2001;  96 1877-1880
    CrossrefPubMedGoogle Scholar
  • 23 Lee J D, Yun M, Lee J M et al.. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography.  Eur J Nucl Med Mol Imaging. 2004;  31 1621-1630
    CrossrefPubMedGoogle Scholar
  • 24 Rose A T, Rose D M, Pinson C W et al.. Hepatocellular carcinoma outcomes based on indicated treatment strategy.  Am Surg. 1998;  64 1128-1134
    PubMedGoogle Scholar
  • 25 Sugiyama M, Sakahara H, Torizuka T et al.. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma.  J Gastroenterol. 2004;  39 961-968
    CrossrefPubMedGoogle Scholar
  • 26 Ruers T, Bleichrodt R P. Treatment of liver metastases, an update on the possibilities and results.  Eur J Cancer. 2002;  38 1023-1033
    CrossrefPubMedGoogle Scholar
  • 27 Kostakoglu L, Goldsmith S J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.  J Nucl Med. 2003;  44 224-239
    PubMedGoogle Scholar
  • 28 Delbeke D, Martin W H. PET and PET-CT for evaluation of colorectal carcinoma.  Semin Nucl Med. 2004;  34 209-223
    CrossrefPubMedGoogle Scholar
  • 29 Antoch G, Vogt F M, Veit P et al.. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures.  J Nucl Med. 2005;  46 520-525
    PubMedGoogle Scholar
  • 30 Vitola J V, Delbeke D, Meranze S G et al.. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization.  Cancer. 1996;  78 2216-2222
    CrossrefPubMedGoogle Scholar
  • 31 Langenhoff B S, Oyen W JG, Jager G J et al.. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.  J Clin Oncol. 2002;  20 4453-4458
    CrossrefPubMedGoogle Scholar
  • 32 Blokhuis T J, van der Schaaf M C, van den Tol M P et al.. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluroglucose scanning.  Scand J Gastroenterol Suppl. 2004;  241 93-97
    PubMedGoogle Scholar
  • 33 Anderson G S, Brinkman F, Soulen M C et al.. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.  Clin Nucl Med. 2003;  28 192-197
    CrossrefPubMedGoogle Scholar
  • 34 Wong C Y, Salem R, Raman S, Gates V L, Dworkin H J. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.  Eur J Nucl Med Mol Imaging. 2002;  29 815-820
    CrossrefPubMedGoogle Scholar
  • 35 Wong C Y, Salem R, Quing F et al.. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.  J Nucl Med. 2004;  45 1892-1897
    PubMedGoogle Scholar
  • 36 Popperl G, Helmberger T, Munzing W et al.. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors.  Cancer Biother Radiopharm. 2005;  20 200-208
    CrossrefPubMedGoogle Scholar
  • 37 Torizuka T, Tamaki N, Inokuma T et al.. Value of fluorine-18-PET to monitor hepatocellular carcinoma after interventional therapy.  J Nucl Med. 1994;  35 1965-1969
    PubMedGoogle Scholar

Robert S HellmanM.D. 

Nuclear Medicine, Froedtert Hospital

9200 W. Wisconsin Avenue, Milwaukee, WI 53226

      >